TGFB1 and cancer: Because TAK1 was originally identified as a kinase activated by TGF-β, an important EMT promoter in diverse cancer types, it is not surprising that inhibition of TAK1 activity could reverse the EMT phenotype and re-activate E-cadherin expression.